Drugs / 5HTP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03574948 | Dec 2018 → Feb 2021 | Crohn disease, ulcerative colitis | University Hospital, Ghent | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT00100464 | Nov 2000 → Dec 2003 | obstructive sleep apnea syndrome | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06718452 | Apr → Oct 2026 expected | tinnitus | University of Campania Luigi Vanvitelli | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04000919 Comparator | Jun 2019 → Jun 2023 | spinal cord injury | Jessica M D'Amico | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-HTP | “The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals...” NCT04000919 ↗4“5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)” NCT04000919 ↗ |
| Known as | 5-hydroxytryptophan | “The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals...” NCT04000919 ↗1“The medications being studied are paroxetine, a commonly used antidepressant, and 5 hydroxy-tryptophan (5HTP)” NCT00100464 ↗ |
| Modality | Other / unclassified | “essential amino-acid” NCT03574948 ↗ |
| Route | Oral | “100 mg oral 5-hydroxytryptophan” PMID 35940251 ↗ Aug 2022 |